Skip to main content

Posts tagged with "Business and Markets"

  • Business and Markets

    Did Pfizer Cut Back Some of Its Best Compounds?

    John LaMattina has a look at Pfizer’s oncology portfolio, and what their relentless budget-cutting has been doing to it. The company is taking some criticism for having outlicensed two compounds (tremelimumab to AstraZeneca and neratinib to Puma) which seem to be performing very well after Pfizer ditched them. Here’s LaMattina (a former… Read More
  • Business and Markets

    Med-Chem and Trucking, Together At Last

    One of my standard lines (in presentations or lab conversation), when referring to some research that just flat-out isn’t working, is that I should chuck it all and go to truck-driving school just like my mother always wanted. (She actually didn’t, in case you’re wondering!) The similarities between organic chemistry and truck dri… Read More
  • Business and Markets

    Amgen Cuts Hard

    Amgen cuts over 2,500 jobs. Amgen completely shuts down its big facilities in Washington state and Colorado. Amgen’s stock goes up nearly 7% in one day, adding about five (corrected late-night mistake) billion dollars in market cap. And there you have it. That’s the industry. As this FierceBiotech piece says, Amgen’s big sharehold… Read More
  • Business and Markets

    Targacept Comes Up Empty, Yet Again

    Targacept’s attempt to salvage something by testing TC-5214 for overactive bladder has failed. John Carroll at FierceBiotech counts eight straight failed clinical trials from this company: a record? I don’t see anyone beating that very easily, that’s for sure. Nicotinic receptors have proven to be a very, very difficult field to w… Read More
  • Business and Markets

    The Antibiotic Gap: It’s All of the Above

    Here’s a business-section column at the New York Times on the problem of antibiotic drug discovery. To those of us following the industry, the problems of antibiotic drug discovery are big pieces of furniture that we’ve lived with all our lives; we hardly even notice if we bump into them again. You’d think that readers… Read More
  • Business and Markets

    Neratinib Comes Through For Puma

    Yet another entry in the “Why do people keep investing in biopharma?” files. Take a look at the case of Puma Biotechnology. Their stock was as high as $140/share earlier in the year, and it gradually deflated to the high 50s/low 60s as time went on. But yesterday, after hours, they reported unexpectedly good Phase… Read More
  • Business and Markets

    How Many Biopharma Employees Would Rather Be Working Somewhere Else?

    How many people working in the biopharma industry would jump to another company if they could? According to this survey, it’s just over half: well above the average set by other industry sectors. The usual reasons are cited, in part (pay, opportunity for advancement). But two factors that seemed unusually prominent in our industry were… Read More
  • Business and Markets

    The Hep C Field Gets Nastier By the Minute

    What a mess there is in the hepatitis C world. Gilead is, famously, dominating the market with Sovaldi, whose price has set off all sorts of cost/benefit debates. The companies competing with them are scrambling to claim positions, and the Wall Street Journal says that AbbVie is really pulling out all the stops. Try this… Read More
  • Business and Markets

    Allergan Twists and Turns

    It’s getting nasty over at Allergan. They’re still trying to fight off a takeover attempt by Valeant, making the case that the company’s R&D efforts are not a waste of money (which, only slightly simplified, is the Valeant position regarding every company they’re taking over). But Allergan’s had a lot of trouble g… Read More
  • Academia (vs. Industry)

    The Prospects of an Academic Job

    Over the years, there have been more comments than anyone can count here on the often-grim employment picture for chemistry and biology employment in biopharma. Plenty of people here (myself included) can speak from experience. But we should also remember that the academic job market in the biomedical sciences is in awful shape, too, unfortunately. Read More